Scarica l'app Stockscreener
34.13
0.23%
0.22
Vera Therapeutics Inc Borsa (VERA) Ultime notizie
J.P. Morgan Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $86 - Moomoo
Vera Therapeutics (VERA) Is Down 11.6% After Wider Q1 Loss Highlights Rising Cost Burden - Sahm
VERA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
VERA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Vera Therapeutics, Inc.Class A Common Stock (NQ: VERA - FinancialContent
UBS Group AG Boosts Position in Vera Therapeutics, Inc. $VERA - MarketBeat
Why (VERA) Price Action Is Critical for Tactical Trading - Stock Traders Daily
T. Rowe Price (VERA) reports 4.57M shares, 6.4% ownership (Amendment) - Stock Titan
Evercore Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $91 - Moomoo
Vera Therapeutics president and CEO sells $679,747 in stock By Investing.com - Investing.com Canada
Vera Therapeutics president and CEO sells $679,747 in stock - Investing.com UK
Vera Therapeutics (VERA) CEO sells 18,500 shares under 10b5-1 plan - Stock Titan
H.C. Wainwright Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $110 - Moomoo
[144] Vera Therapeutics, Inc. SEC Filing - Stock Titan
Vera Therapeutics (VERA) Receives a Buy from Guggenheim - The Globe and Mail
TradingKey - TradingKey
Guggenheim Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $56 - Moomoo
The Bull Case For Vera Therapeutics (VERA) Could Change Following Atacicept’s FDA Priority Review And Ramp-Up - Yahoo! Finance Canada
A Look At Vera Therapeutics (VERA) Valuation After FDA Priority Review For Atacicept In IgA Nephropathy - Sahm
Does Vera’s Widening Quarterly Net Loss Reframe the Bull Case for Vera Therapeutics (VERA)? - Sahm
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vera Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4) - marketscreener.com
Vera Therapeutics announces inducement grants under Nasdaq listing rule 5635(C)(4) - TradingView
Ten new hires get Vera stock awards tied to 60,375 shares - Stock Titan
TD Cowen Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $73 - Moomoo
Vera Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Vera Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo
Vera Therapeutics (VERA) ramps spending as atacicept nears key FDA decision - Stock Titan
LifeSci Capital Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $90 - Moomoo
Vera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Vera Therapeutics, Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Kidney disease drug gets July 7 FDA date as Vera readies launch - Stock Titan
Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results - marketscreener.com
[8-K] Vera Therapeutics, Inc. Reports Material Event - Stock Titan
Press Release: Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results - Moomoo
Vera Therapeutics faces earnings test ahead of FDA verdict - Investing.com UK
Vera Therapeutics faces earnings test ahead of FDA verdict By Investing.com - Investing.com South Africa
Understanding Momentum Shifts in (VERA) - Stock Traders Daily
Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference - The Manila Times
Vera Therapeutics to present May 13 at Bank of America health conference - Stock Titan
IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsight - GlobeNewswire Inc.
Pictet Asset Management Holding SA Cuts Stake in Vera Therapeutics, Inc. $VERA - MarketBeat
Vera Therapeutics (VERA) to Release Earnings on Tuesday - MarketBeat
HC Wainwright & Co. Maintains Vera Therapeutics (VERA) Buy Recommendation - MSN
2.25%
0.46%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):